Media coverage about Flexion Therapeutics (NASDAQ:FLXN) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 45.4770454332684 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s analysis:
- 4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings (finance.yahoo.com)
- Flexion Therapeutics Inc (FLXN) Price Holds Above Ichimoku Cloud – Financial News Review (finnewsreview.com)
- Flexion Therapeutics, Inc. (NASDAQ:FLXN) Rating Lowered to Sell at Zacks Investment Research (americanbankingnews.com)
- Biotech Movers: Ocular, Alder, Flexion – TheStreet.com (thestreet.com)
FLXN has been the subject of several analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $34.00 target price on shares of Flexion Therapeutics in a research note on Wednesday, April 26th. Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a research note on Friday, July 7th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. BMO Capital Markets reissued a “buy” rating on shares of Flexion Therapeutics in a research note on Tuesday, June 27th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $34.00 target price on shares of Flexion Therapeutics in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Flexion Therapeutics has a consensus rating of “Buy” and an average price target of $31.10.
Flexion Therapeutics (NASDAQ:FLXN) traded up 1.28% on Wednesday, hitting $23.66. 63,679 shares of the stock were exchanged. Flexion Therapeutics has a 52 week low of $15.22 and a 52 week high of $29.41. The company’s 50-day moving average is $19.72 and its 200-day moving average is $20.79. The company’s market cap is $751.37 million.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.02. On average, analysts predict that Flexion Therapeutics will post ($3.56) earnings per share for the current year.
In other news, insider Michael D. Clayman purchased 5,000 shares of the business’s stock in a transaction dated Monday, June 5th. The stock was bought at an average cost of $17.23 per share, with a total value of $86,150.00. Following the purchase, the insider now directly owns 20,146 shares of the company’s stock, valued at $347,115.58. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark Stejbach purchased 1,580 shares of the business’s stock in a transaction dated Friday, June 16th. The shares were purchased at an average cost of $17.02 per share, with a total value of $26,891.60. The disclosure for this purchase can be found here. 15.98% of the stock is currently owned by corporate insiders.
WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Flexion Therapeutics (FLXN) Stock Price” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://transcriptdaily.com/2017/07/19/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-flexion-therapeutics-flxn-stock-price.html.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.